首页/数据集/Clonal Evolution underlying leukemia progression and Richter transformation in ibrutinib-relapsed CLL patients

Clonal Evolution underlying leukemia progression and Richter transformation in ibrutinib-relapsed CLL patients

NIAID Data Ecosystem2026-03-10 收录

白血病克隆演化

BTK抑制剂

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA381632 数据链接链接失效反馈

官方服务：

资源简介：

Serial samples from CLL patients who relapsed post treatment with BTK-inhibitor, Ibrutinib (Ibr), sequenced using UCM-OncoPlus (a 1200 hybrid capture gene panel from University of Chicago)

应用场景：

创建时间：

2017-04-04

白血病克隆演化

白血病治疗抵抗

All cancers emerge following a period of clonal selection and subsequent clonal expansion. Whilst the evolutionary principles imparted by genetic intra-tumour heterogeneity (ITH) are becoming increasi

NIAID Data Ecosystem40

Assessing the mechanism of action of BTK inhibitor, G7744

BTK抑制剂

小鼠疾病模型

Purpose: to investigate the method of action (MOA) of BTK small molecule inhibitor, G7744, in a pre-clinical mouse lupus model (NZB/W F1). Hypothesis: BTK inhibition will affect B cell and myeloid cel

NIAID Data Ecosystem30

Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia. Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia

白血病克隆演化

癌症基因组数据

Despite high survival rates in pediatric acute lymphoblastic leukemia (ALL), relapse remains a leading cause of cancer-related death in children. Many patients suffer from adverse drug effects during

NIAID Data Ecosystem30

Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance

BTK抑制剂

药物耐药性

Despite significant efficacy, one of the major limitations of small-molecule Bruton’s tyrosine kinase (BTK) agents is the presence of clinically acquired resistance, which remains a major clinical cha

Figshare2022-05-20 更新30

Whole Exome Sequencing of paired diagnosis and relapse specimens from acute myeloid leukemia (AML) patients treated with venetoclax plus azacitidine

白血病克隆演化

肿瘤耐药机制

To understand clonal dynamics during relapse response to the venetoclax plus azacitidine therapy in AML, we sorted immunophenotypically primitive and monocytic subpopulations at diagnosis, and the dom

NIAID Data Ecosystem30

Clonal Evolution underlying leukemia progression and Richter transformation in ibrutinib-relapsed CLL patients

资源简介：

相关数据集